$0.67
(23.26%)
0.06%
Add to watchlist
Create an alert
Stocks and Shares ISAQuince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
Company Information
About this company
Key people
Charles S. Ryan
President
Dirk Thye
Chief Executive Officer, Chief Medical Officer, Director
Brendan Hannah
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
David A. Lamond
Independent Chairman of the Board
Una Ryan
Lead Independent Director
Luca Benatti
Independent Director
June Bray
Independent Director
Margaret A. Mcloughlin
Independent Director
Click to see more
Key facts
- Shares in issue55.68m
- EPICQNCX
- ISINUS22053A1079
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$167.60m
- Employees36
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.